The drug not only reduced albuminuria, mesangial collagen IV deposition, and oxidative-nitrosative stress in streptozotocin (STZ)-treated mice (Advani et al. 2011) but also revealed an inhibitory effect on diabetes-associated renal growth in STZ-treated rats, partly due to modulation of the EGF-EGFR axis (Gilbert et al. 2011), further supporting the potential of vorinostat as a treatment strategy for chronic kidney disease and the important role of the EGF pathway in CKD. Here, EGF is linked to chronic kidney disease.